Real estate
At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.
Facility to cement Park’s position in UK life sciences ecosystem
A*STAR’s Institute of Microelectronics (IME) and One BioMed, an A*STAR spin-off, launched a S$9 million joint lab on Thursday (29 November).
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.
Asia-Pacific specialist CRO Novotech announced today that clinical staff numbers in its Seoul, South Korea centre are now at 41, with 81 clinical research projects now completed.
Opening ceremony of new high-tech facility for the aseptic filling and freeze-drying of drug products.
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
Boston Scientific’s restructuring will take place over a three-year period. The company expects it overall employee base to remain relatively unchanged when it is complete, although some losses are expected.
With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.
Three Boston-area developers, King Street Properties, Mugar Enterprises and the DiStefano family, have proposed a possible new life sciences campus in the area to compete with Kendall Square. It is a 607,900-square-foot campus on a 4.3-acre site in Allston, an officially recognized neighborhood of Boston.
PRESS RELEASES